id
stringlengths 7
11
| context
stringlengths 24
527
| is_mult_event
bool 2
classes | annotations
list |
|---|---|---|---|
6519218_1 | In a 61-year-old man receiving chronic low-dosage amiodarone an interstitial pneumopathy was observed. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"observed\"]], \"start\": [[93]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"chronic low-dosage amiodarone\"]], \"start\": [[31]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"amiodarone\"]], \"start\": [[50]], \"entity_id\": [\"T9\"]}, \"Dosage\": {\"text\": [[\"low-dosage\"]], \"start\": [[39]], \"entity_id\": [\"T10\"]}}, \"Subject\": {\"text\": [[\"a 61-year-old man\"]], \"start\": [[3]], \"entity_id\": [\"T4\"], \"Age\": {\"text\": [[\"61-year-old\"]], \"start\": [[5]], \"entity_id\": [\"T7\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[17]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"interstitial pneumopathy\"]], \"start\": [[64]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
12126225_2 | A 75-year-old man developed bilateral lower leg edema 6 months after switching from troglitazone to pioglitazone. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[18]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"A 75-year-old man\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"75-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T7\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[14]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"bilateral lower leg edema\"]], \"start\": [[28]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"6 months after switching from troglitazone to pioglitazone\"]], \"start\": [[54]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"pioglitazone\"], [\"6 months\"], [\"troglitazone\"]], \"start\": [[100], [54], [84]], \"entity_id\": [\"T9\", \"T10\", \"T12\"]}}}"
}
]
}
] |
10475726_1 | An acute ischaemic event associated with the use of venlafaxine: a case report and proposed pathophysiological mechanisms. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[25]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"venlafaxine\"]], \"start\": [[52]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"venlafaxine\"]], \"start\": [[52]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"An acute ischaemic event\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"a case\"]], \"start\": [[65]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
21751666_5 | Oseltamivir was effective for post-exposure prophylaxis of H1N1 in close contact. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"post-exposure prophylaxis\"]], \"start\": [[30]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"Oseltamivir\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Disorder\": {\"text\": [[\"H1N1\"]], \"start\": [[59]], \"entity_id\": [\"T5\"]}, \"Drug\": {\"text\": [[\"Oseltamivir\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
19365885_1 | Herein, we present a patient with severe and prolonged hypoglycemia after long-acting octreotide treatment. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[68]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"long-acting octreotide treatment\"]], \"start\": [[74]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"octreotide\"]], \"start\": [[86]], \"entity_id\": [\"T8\"]}}, \"Subject\": {\"text\": [[\"a patient\"]], \"start\": [[19]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"severe and prolonged hypoglycemia\"]], \"start\": [[34]], \"entity_id\": [\"T6\"]}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[34]], \"entity_id\": [\"T7\"], \"value\": \"High\"}}"
}
]
}
] |
25417855_1 | Worsening pneumonitis due to a pharmacokinetic drug-drug interaction between everolimus and voriconazole in a renal transplant patient. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"due to\"]], \"start\": [[22]], \"entity_id\": [\"T9\"]}, \"Subject\": {\"text\": [[\"a renal transplant patient\"]], \"start\": [[108]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"Worsening pneumonitis\"]], \"start\": [[0]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"pharmacokinetic drug-drug interaction between everolimus and voriconazole\"]], \"start\": [[31]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"everolimus\"], [\"voriconazole\"]], \"start\": [[77], [92]], \"entity_id\": [\"T11\", \"T12\"]}, \"Disorder\": {\"text\": [[\"renal transplant\"]], \"start\": [[110]], \"entity_id\": [\"T14\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"interaction\"]], \"start\": [[57]], \"entity_id\": [\"T13\"]}, \"Drug\": {\"text\": [[\"everolimus\"], [\"voriconazole\"]], \"start\": [[77], [92]], \"entity_id\": [\"T11\", \"T12\"]}}]}}"
}
]
}
] |
11576059_1 | Vocal cord paralysis as a consequence of peritonsillar infiltration with bupivacaine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"consequence\"]], \"start\": [[26]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Vocal cord paralysis\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"peritonsillar infiltration with bupivacaine\"]], \"start\": [[41]], \"entity_id\": [\"T5\"], \"Route\": {\"text\": [[\"peritonsillar infiltration\"]], \"start\": [[41]], \"entity_id\": [\"T6\"]}, \"Drug\": {\"text\": [[\"bupivacaine\"]], \"start\": [[73]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
1267457_3 | The sulfonamides are the best verified drug-trigger for erythema multiforme and Stevens-Johnson syndrome. | false | [
{
"events": [
{
"event_id": "E2",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"drug-trigger\"]], \"start\": [[39]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"sulfonamides\"]], \"start\": [[4]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"sulfonamides\"]], \"start\": [[4]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"erythema multiforme and Stevens-Johnson syndrome\"]], \"start\": [[56]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
576675_2 | Edema associated with ibuprofen therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[6]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Edema\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"ibuprofen\"]], \"start\": [[22]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"ibuprofen\"]], \"start\": [[22]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
3365032_1 | A patient is presented with typical hyperthyroidism, who developed a severe proximal muscle weakness and a raised creatine phosphokinase after treatment for hyperthyroidism with propylthiouracil (100 mg orally, three times a day). | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[137]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"A patient is presented with typical hyperthyroidism\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"severe proximal muscle weakness and a raised creatine phosphokinase\"]], \"start\": [[69]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"treatment for hyperthyroidism with propylthiouracil (100 mg orally, three times a day)\"]], \"start\": [[143]], \"entity_id\": [\"T11\"], \"Disorder\": {\"text\": [[\"hyperthyroidism\"], [\"typical hyperthyroidism\"]], \"start\": [[157], [28]], \"entity_id\": [\"T13\", \"T18\"]}, \"Drug\": {\"text\": [[\"propylthiouracil\"]], \"start\": [[178]], \"entity_id\": [\"T14\"]}, \"Dosage\": {\"text\": [[\"100 mg\"]], \"start\": [[196]], \"entity_id\": [\"T15\"]}, \"Route\": {\"text\": [[\"orally\"]], \"start\": [[203]], \"entity_id\": [\"T16\"]}, \"Freq\": {\"text\": [[\"three times a day\"]], \"start\": [[211]], \"entity_id\": [\"T17\"]}}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[69]], \"entity_id\": [\"T12\"], \"value\": \"Medium\"}}"
}
]
}
] |
12243603_7 | Atorvastatin is the most potent of this class of agents currently available and is commonly used in the treatment of hyperlipidemia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"treatment\"]], \"start\": [[104]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"Atorvastatin\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"hyperlipidemia\"]], \"start\": [[117]], \"entity_id\": [\"T6\"]}, \"Drug\": {\"text\": [[\"Atorvastatin\"]], \"start\": [[0]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"most potent\"]], \"start\": [[20]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
2935070_2 | However, there are few reports in the literature of ampicillin as a cause of acute interstitial nephritis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"cause\"]], \"start\": [[68]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"ampicillin\"]], \"start\": [[52]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"ampicillin\"]], \"start\": [[52]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"acute interstitial nephritis\"]], \"start\": [[77]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
2956288_3 | Optic neuropathy in ethambutol-treated renal tuberculosis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"treated\"]], \"start\": [[31]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Optic neuropathy\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"ethambutol\"]], \"start\": [[20]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"ethambutol\"]], \"start\": [[20]], \"entity_id\": [\"T7\"]}, \"Disorder\": {\"text\": [[\"renal tuberculosis\"]], \"start\": [[39]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
7779233_2 | This case study describes an atypical case of refractory, sodium warfarin-induced necrotizing fasciitis and myonecrosis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[74]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"sodium warfarin\"]], \"start\": [[58]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"sodium warfarin\"]], \"start\": [[58]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"necrotizing fasciitis and myonecrosis\"]], \"start\": [[82]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
8384030_4 | OBJECTIVE: To report a case of possible foscarnet-induced severe hypomagnesemia and other electrolyte disorders. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[50]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"a case\"]], \"start\": [[21]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"foscarnet\"]], \"start\": [[40]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"foscarnet\"]], \"start\": [[40]], \"entity_id\": [\"T13\"]}}, \"Effect\": {\"text\": [[\"severe hypomagnesemia and other electrolyte disorders\"]], \"start\": [[58]], \"entity_id\": [\"T9\"]}, \"Speculated\": {\"text\": [[\"possible\"]], \"start\": [[31]], \"entity_id\": [\"T6\"], \"value\": true}}"
}
]
}
] |
7673653_3 | However, the occurrence and management of akathisia induced by fluvoxamine have not been described. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[52]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"akathisia\"]], \"start\": [[42]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"fluvoxamine\"]], \"start\": [[63]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"fluvoxamine\"]], \"start\": [[63]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
17009081_3 | Nephrotic syndrome associated with interferon-beta-1b therapy for multiple sclerosis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated with\"]], \"start\": [[19]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Nephrotic syndrome\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"interferon-beta-1b therapy\"]], \"start\": [[35]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"interferon-beta-1b\"]], \"start\": [[35]], \"entity_id\": [\"T7\"]}, \"Disorder\": {\"text\": [[\"multiple sclerosis.\"]], \"start\": [[66]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
17438184_3 | OBSERVATIONS: A 48-year-old woman presented with disfiguring facial edema 10 weeks after she began antiviral therapy with peginterferon alfa-2a and ribavirin for chronic hepatitis C infection. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[83]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"A 48-year-old woman\"]], \"start\": [[14]], \"entity_id\": [\"T9\"], \"Age\": {\"text\": [[\"48-year-old\"]], \"start\": [[16]], \"entity_id\": [\"T13\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[28]], \"entity_id\": [\"T14\"]}}, \"Effect\": {\"text\": [[\"disfiguring facial edema\"]], \"start\": [[49]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"10 weeks\", \"antiviral therapy with peginterferon alfa-2a and ribavirin\"]], \"start\": [[74, 99]], \"entity_id\": [\"T11\"], \"Disorder\": {\"text\": [[\"chronic hepatitis C infection\"]], \"start\": [[162]], \"entity_id\": [\"T12\"]}, \"Time_elapsed\": {\"text\": [[\"10 weeks\"]], \"start\": [[74]], \"entity_id\": [\"T15\"]}, \"Drug\": {\"text\": [[\"peginterferon alfa-2a\"], [\"ribavirin\"]], \"start\": [[122], [148]], \"entity_id\": [\"T17\", \"T18\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[144]], \"entity_id\": [\"T16\"]}, \"Drug\": {\"text\": [[\"peginterferon alfa-2a\"], [\"ribavirin\"]], \"start\": [[122], [148]], \"entity_id\": [\"T17\", \"T18\"]}}]}}"
}
]
}
] |
4095247_3 | Two of these patients, who also received the anti-emetic prochlorperazine, lost consciousness for 48-72 h and then fully recovered. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"lost\"]], \"start\": [[75]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"Two of these patients\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Population\": {\"text\": [[\"Two\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}, \"Treatment\": {\"text\": [[\"anti-emetic prochlorperazine\"]], \"start\": [[45]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"prochlorperazine\"]], \"start\": [[57]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"lost consciousness for 48-72 h and then fully recovered\"]], \"start\": [[75]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
16986159_1 | We present a depressive patient who developed mild parkinsonian signs and camptocormia after the introduction of olanzapine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[36]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"mild parkinsonian signs and camptocormia\"]], \"start\": [[46]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"introduction of olanzapine\"]], \"start\": [[97]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"olanzapine\"]], \"start\": [[113]], \"entity_id\": [\"T11\"]}, \"Disorder\": {\"text\": [[\"depressive\"]], \"start\": [[13]], \"entity_id\": [\"T12\"]}}, \"Subject\": {\"text\": [[\"depressive patient\"]], \"start\": [[13]], \"entity_id\": [\"T8\"]}, \"Severity\": {\"text\": [[\"mild\"]], \"start\": [[46]], \"entity_id\": [\"T10\"], \"value\": \"Medium\"}}"
}
]
}
] |
7379406_3 | The case report discussed is, to our knowledge, the third of its kind regarding bone fluorosis resulting from use of this nicotinic derivative. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"use\"]], \"start\": [[110]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"nicotinic derivative\"]], \"start\": [[122]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"nicotinic derivative\"]], \"start\": [[122]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"bone fluorosis\"]], \"start\": [[80]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
17266059_3 | We report a case of Thrombotic Thrombocytopenic Purpura occurring as an allergic response to trimethoprim-sulfamethoxazole therapy (Bactrim, Septra) in a Jehovah's Witness patient. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"to\"]], \"start\": [[90]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Thrombotic Thrombocytopenic Purpura\", \"allergic response\"]], \"start\": [[20, 72]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"trimethoprim-sulfamethoxazole\"]], \"start\": [[93]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"trimethoprim\"], [\"sulfamethoxazole\"]], \"start\": [[93], [106]], \"entity_id\": [\"T8\", \"T9\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"-\"]], \"start\": [[105]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"trimethoprim\"], [\"sulfamethoxazole\"]], \"start\": [[93], [106]], \"entity_id\": [\"T8\", \"T9\"]}}]}, \"Subject\": {\"text\": [[\"Jehovah's Witness patient\"]], \"start\": [[154]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
11144696_3 | A 25-year-old white woman with chronic depression was treated with venlafaxine 150 mg/d and trimipramine 50 mg/d. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"treated\"]], \"start\": [[54]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"venlafaxine 150 mg/d and trimipramine 50 mg/d\"]], \"start\": [[67]], \"entity_id\": [\"T10\"], \"Disorder\": {\"text\": [[\"chronic depression\"]], \"start\": [[31]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"venlafaxine\"], [\"trimipramine\"]], \"start\": [[67], [92]], \"entity_id\": [\"T15\", \"T16\"]}, \"Dosage\": {\"text\": [[\"150 mg/d\"], [\"50 mg/d\"]], \"start\": [[79], [105]], \"entity_id\": [\"T17\", \"T20\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[88]], \"entity_id\": [\"T14\"]}, \"Drug\": {\"text\": [[\"venlafaxine\"], [\"trimipramine\"]], \"start\": [[67], [92]], \"entity_id\": [\"T15\", \"T16\"]}}]}, \"Subject\": {\"text\": [[\"A 25-year-old white woman with chronic depression\"]], \"start\": [[0]], \"entity_id\": [\"T7\"], \"Age\": {\"text\": [[\"25-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T11\"]}, \"Race\": {\"text\": [[\"white\"]], \"start\": [[14]], \"entity_id\": [\"T12\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[20]], \"entity_id\": [\"T13\"]}}}"
}
]
}
] |
12078977_1 | A 31-year-old female developed multiple episodes of grand mal seizures after combination chemotherapy with cisplatin, vinblastine and bleomycin for germ cell ovarian cancer stage Ic. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[21]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"A 31-year-old female\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Age\": {\"text\": [[\"31-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T9\"]}, \"Gender\": {\"text\": [[\"female\"]], \"start\": [[14]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"multiple episodes of grand mal seizures\"]], \"start\": [[31]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"combination chemotherapy with cisplatin, vinblastine and bleomycin\"]], \"start\": [[77]], \"entity_id\": [\"T8\"], \"Disorder\": {\"text\": [[\"germ cell ovarian cancer stage Ic\"]], \"start\": [[148]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"bleomycin\"], [\"vinblastine\"], [\"cisplatin\"]], \"start\": [[134], [118], [107]], \"entity_id\": [\"T12\", \"T13\", \"T14\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"combination\"]], \"start\": [[77]], \"entity_id\": [\"T15\"]}, \"Drug\": {\"text\": [[\"cisplatin\"], [\"vinblastine\"], [\"bleomycin\"]], \"start\": [[107], [118], [134]], \"entity_id\": [\"T14\", \"T13\", \"T12\"]}}]}}"
}
]
}
] |
8604715_1 | Nephrogenic diabetes insipidus and renal tubular acidosis secondary to foscarnet therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"secondary\"]], \"start\": [[58]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"foscarnet\"]], \"start\": [[71]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"foscarnet\"]], \"start\": [[71]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"Nephrogenic diabetes insipidus and renal tubular acidosis\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
16765687_1 | PURPOSE: Topiramate-induced angle-closure glaucoma (TiACG) is believed to be related to its sulfonamide moiety. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[20]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Topiramate\"]], \"start\": [[9]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Topiramate\"]], \"start\": [[9]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"angle-closure glaucoma (TiACG)\"]], \"start\": [[28]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
18344455_4 | These toxicities resolved after the cessation of anticonvulsants, and her seizures were managed acutely with scheduled lorazepam. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"managed\"]], \"start\": [[88]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"lorazepam\"]], \"start\": [[119]], \"entity_id\": [\"T7\"], \"Disorder\": {\"text\": [[\"seizures\"]], \"start\": [[74]], \"entity_id\": [\"T5\"]}, \"Drug\": {\"text\": [[\"lorazepam\"]], \"start\": [[119]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
2728526_4 | This article reports the occurrence of rifampin-associated thrombocytopenia in an indigent patient after a four-month lapse in therapy for pulmonary tuberculosis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[48]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"rifampin\", \"after a four-month lapse in therapy for pulmonary tuberculosis\"]], \"start\": [[39, 99]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"rifampin\"]], \"start\": [[39]], \"entity_id\": [\"T6\"]}, \"Time_elapsed\": {\"text\": [[\"four-month\"]], \"start\": [[107]], \"entity_id\": [\"T11\"]}, \"Disorder\": {\"text\": [[\"pulmonary tuberculosis\"]], \"start\": [[139]], \"entity_id\": [\"T12\"]}}, \"Effect\": {\"text\": [[\"thrombocytopenia\"]], \"start\": [[59]], \"entity_id\": [\"T9\"]}, \"Subject\": {\"text\": [[\"an indigent patient\"]], \"start\": [[79]], \"entity_id\": [\"T10\"]}}"
}
]
}
] |
6721543_1 | Drug-induced psychosis resulted from the administration of quinacrine hydrochloride at a dosage of 100 mg twice daily for the treatment of discoid lupus. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[5]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"administration of quinacrine hydrochloride at a dosage of 100 mg twice daily\"]], \"start\": [[41]], \"entity_id\": [\"T3\"], \"Dosage\": {\"text\": [[\"100 mg\"]], \"start\": [[99]], \"entity_id\": [\"T7\"]}, \"Freq\": {\"text\": [[\"twice daily\"]], \"start\": [[106]], \"entity_id\": [\"T8\"]}, \"Disorder\": {\"text\": [[\"discoid lupus\"]], \"start\": [[139]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"quinacrine hydrochloride\"]], \"start\": [[59]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"psychosis resulted\"]], \"start\": [[13]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
10688731_3 | We report a case of a scleroderma-like reaction induced by long-term administration of UFT. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[48]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"a scleroderma-like reaction\"]], \"start\": [[20]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"long-term administration of UFT\"]], \"start\": [[59]], \"entity_id\": [\"T5\"], \"Duration\": {\"text\": [[\"long-term\"]], \"start\": [[59]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"UFT\"]], \"start\": [[87]], \"entity_id\": [\"T8\"]}}, \"Subject\": {\"text\": [[\"a case\"]], \"start\": [[10]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
16109609_4 | We report four cases of hemodynamically significant pericardial effusion in patients with refractory lymphoma who were receiving gemcitabine, all of whom had a history of mediastinal radiation without subcarinal blocking. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"in\"]], \"start\": [[73]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"hemodynamically significant pericardial effusion\"]], \"start\": [[24]], \"entity_id\": [\"T3\"]}, \"Subject\": {\"text\": [[\"had a history of mediastinal radiation without subcarinal blocking\"]], \"start\": [[154]], \"entity_id\": [\"T4\"], \"Disorder\": {\"text\": [[\"mediastinal radiation without subcarinal blocking\"]], \"start\": [[171]], \"entity_id\": [\"T8\"]}, \"Population\": {\"text\": [[\"four\"]], \"start\": [[10]], \"entity_id\": [\"T1\"]}}, \"Treatment\": {\"text\": [[\"gemcitabine\"]], \"start\": [[129]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"refractory lymphoma\"]], \"start\": [[90]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"gemcitabine\"]], \"start\": [[129]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
10679548_1 | Both had impaired lung function and abnormal computed tomographic scans, and their condition improved when nitrofurantoin was withdrawn and corticosteroid treatment commenced. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"improved\"]], \"start\": [[93]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"nitrofurantoin was withdrawn and corticosteroid treatment commenced\"]], \"start\": [[107]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"corticosteroid\"], [\"nitrofurantoin\"]], \"start\": [[140], [107]], \"entity_id\": [\"T11\", \"T12\"]}, \"Disorder\": {\"text\": [[\"impaired lung function\"]], \"start\": [[9]], \"entity_id\": [\"T13\"]}}, \"Subject\": {\"text\": [[\"Both had impaired lung function and abnormal computed tomographic scans\"]], \"start\": [[0]], \"entity_id\": [\"T7\"], \"Population\": {\"text\": [[\"Both\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}, \"Disorder\": {\"text\": [[\"abnormal computed tomographic scans\"]], \"start\": [[36]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
18691992_6 | OBJECTIVE: The purpose of this study was to report the concomitant occurrence of multiple squamous cell carcinomas and diffuse nail hyperpigmentation associated with hydroxyurea treatment, and to describe a successful therapeutic approach using imiquimod 5%. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[150]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"multiple squamous cell carcinomas and diffuse nail hyperpigmentation\"]], \"start\": [[81]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"hydroxyurea\"]], \"start\": [[166]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"hydroxyurea\"]], \"start\": [[166]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
17319250_2 | We present a case report of a patient who developed a prolonged QT while being treated with oral methadone for a chronic pain syndrome. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"treated\"]], \"start\": [[79]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"oral methadone\"]], \"start\": [[92]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"methadone\"]], \"start\": [[97]], \"entity_id\": [\"T7\"]}, \"Route\": {\"text\": [[\"oral\"]], \"start\": [[92]], \"entity_id\": [\"T8\"]}, \"Disorder\": {\"text\": [[\"chronic pain syndrome\"]], \"start\": [[113]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"prolonged QT\"]], \"start\": [[54]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"a patient\"]], \"start\": [[28]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
19897274_3 | In this article, we describe a Japanese patient with severe interstitial pneumonia probably caused by sorafenib treatment for metastatic renal cell carcinoma. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"caused\"]], \"start\": [[92]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"a Japanese patient\"]], \"start\": [[29]], \"entity_id\": [\"T3\"], \"Race\": {\"text\": [[\"Japanese\"]], \"start\": [[31]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"severe interstitial pneumonia\"]], \"start\": [[53]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"sorafenib\"]], \"start\": [[102]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"metastatic renal cell carcinoma\"]], \"start\": [[126]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"sorafenib\"]], \"start\": [[102]], \"entity_id\": [\"T11\"]}}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[53]], \"entity_id\": [\"T9\"], \"value\": \"High\"}, \"Speculated\": {\"text\": [[\"probably\"]], \"start\": [[83]], \"entity_id\": [\"T10\"], \"value\": true}}"
}
]
}
] |
15494638_17 | Neurotoxicity occurs most often with intermittent high dose 5-FU as bolus injection or 24- to 48-h infusions. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"occurs\"]], \"start\": [[14]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Neurotoxicity\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"intermittent high dose 5-FU as bolus injection or 24- to 48-h infusions\"]], \"start\": [[37]], \"entity_id\": [\"T6\"], \"Dosage\": {\"text\": [[\"high dose\"]], \"start\": [[50]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"5-FU\"]], \"start\": [[60]], \"entity_id\": [\"T9\"]}, \"Route\": {\"text\": [[\"injection\"], [\"infusions\"]], \"start\": [[74], [99]], \"entity_id\": [\"T10\", \"T11\"]}}}"
}
]
}
] |
14998226_7 | Lovastatin also reportedly has caused increases in INR when coadministered with warfarin. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"caused\"]], \"start\": [[31]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"Lovastatin\"]], \"start\": [[0]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"Lovastatin\"]], \"start\": [[0]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"increases in INR\"]], \"start\": [[38]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
14998226_10 | Pravastatin does not appear to interact with warfarin but has caused an increased INR when combined with the anticoagulant fluindione. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"caused\"]], \"start\": [[62]], \"entity_id\": [\"T10\"]}, \"Effect\": {\"text\": [[\"increased INR\"]], \"start\": [[72]], \"entity_id\": [\"T11\"]}, \"Treatment\": {\"text\": [[\"Pravastatin\", \"combined with the anticoagulant fluindion\"]], \"start\": [[0, 91]], \"entity_id\": [\"T12\"], \"Drug\": {\"text\": [[\"Pravastatin\"], [\"anticoagulant fluindione\"]], \"start\": [[0], [109]], \"entity_id\": [\"T14\", \"T15\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"combined\"]], \"start\": [[91]], \"entity_id\": [\"T16\"]}, \"Drug\": {\"text\": [[\"Pravastatin\"], [\"anticoagulant fluindione\"]], \"start\": [[0], [109]], \"entity_id\": [\"T14\", \"T15\"]}}]}, \"Negated\": {\"text\": [[\"not\"]], \"start\": [[17]], \"entity_id\": [\"T13\"], \"value\": true}}"
}
]
}
] |
8120934_2 | Bromocriptine-induced schizophrenia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[14]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"Bromocriptine\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"Bromocriptine\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"schizophrenia\"]], \"start\": [[22]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
17873198_2 | Pulmonary toxicity associated with erlotinib. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[19]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Pulmonary toxicity\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"erlotinib\"]], \"start\": [[35]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"erlotinib\"]], \"start\": [[35]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
2442958_1 | Multicentric hepatocellular carcinoma following phosphate diethylstilbestrol therapy for prostatic cancer. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[38]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Multicentric hepatocellular carcinoma\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"phosphate diethylstilbestrol\"]], \"start\": [[48]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"phosphate diethylstilbestrol\"]], \"start\": [[48]], \"entity_id\": [\"T7\"]}, \"Disorder\": {\"text\": [[\"prostatic cancer\"]], \"start\": [[89]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
16025424_1 | Rapid onset of quetiapine-induced diabetic ketoacidosis in an elderly patient: a case report. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[26]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"quetiapine\"]], \"start\": [[15]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"quetiapine\"]], \"start\": [[15]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"diabetic ketoacidosis\"]], \"start\": [[34]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"an elderly patient\"]], \"start\": [[59]], \"entity_id\": [\"T6\"], \"Age\": {\"text\": [[\"elderly\"]], \"start\": [[62]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
3815268_1 | A 57-year-old woman developed pulmonary sarcoidosis during therapy with interferon beta for advanced renal cell carcinoma metastatic to mediastinal lymph nodes. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[20]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"57-year-old woman\"]], \"start\": [[2]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"57-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T8\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[14]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"pulmonary sarcoidosis\"]], \"start\": [[30]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"interferon beta for advanced renal cell carcinoma metastatic to mediastinal lymph nodes\"]], \"start\": [[72]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"advanced renal cell carcinoma metastatic to mediastinal lymph nodes\"]], \"start\": [[92]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"interferon beta\"]], \"start\": [[72]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
9013348_2 | Mesalamine-induced hypersensitivity pneumonitis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[11]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Mesalamine\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Mesalamine\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"hypersensitivity pneumonitis\"]], \"start\": [[19]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
11737689_2 | A girl with cystic fibrosis and cyclic neutropenia developed an erythematous papular eruption without fever or neutrophilia 7 months after commencing therapy with G-CSF. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[51]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"7 months after commencing therapy with G-CSF.\"]], \"start\": [[124]], \"entity_id\": [\"T4\"], \"Disorder\": {\"text\": [[\"cyclic neutropenia\"]], \"start\": [[32]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"G-CSF\"]], \"start\": [[163]], \"entity_id\": [\"T10\"]}, \"Time_elapsed\": {\"text\": [[\"7 months\"]], \"start\": [[124]], \"entity_id\": [\"T11\"]}}, \"Subject\": {\"text\": [[\"A girl with cystic fibrosis and cyclic neutropenia\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Gender\": {\"text\": [[\"girl\"]], \"start\": [[2]], \"entity_id\": [\"T7\"]}, \"Disorder\": {\"text\": [[\"cystic fibrosis\"]], \"start\": [[12]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"erythematous papular eruption without fever or neutrophilia\"]], \"start\": [[64]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
71813_3 | Lichen planus and acne provoked by gold. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"provoked\"]], \"start\": [[23]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Lichen planus and acne\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"gold\"]], \"start\": [[35]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"gold\"]], \"start\": [[35]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
12153007_2 | To the best of our knowledge only two previous cases of AML have been linked to treatment of HCL with purine analogs, both with 2-chlorodeoxyadenosine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"linked\"]], \"start\": [[70]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"AML\"]], \"start\": [[56]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"purine analogs, both with 2-chlorodeoxyadenosine\"]], \"start\": [[102]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"2-chlorodeoxyadenosine\"]], \"start\": [[128]], \"entity_id\": [\"T7\"]}, \"Disorder\": {\"text\": [[\"HCL\"]], \"start\": [[93]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
12656748_3 | There are no previous reports in the literature about the emergence of CML during treatment with hydroxyurea. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"during\"]], \"start\": [[75]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"CML\"]], \"start\": [[71]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"treatment with hydroxyurea\"]], \"start\": [[82]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"hydroxyurea\"]], \"start\": [[97]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
10614572_1 | Intravenous valproate associated with significant hypotension in the treatment of status epilepticus. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[22]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"Intravenous valproate\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Disorder\": {\"text\": [[\"status epilepticus\"]], \"start\": [[82]], \"entity_id\": [\"T6\"]}, \"Route\": {\"text\": [[\"Intravenous\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"valproate\"]], \"start\": [[12]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"significant hypotension\"]], \"start\": [[38]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
17876386_2 | Torsade de pointes associated with moxifloxacin: a rare but potentially fatal adverse event. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[19]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"moxifloxacin\"]], \"start\": [[35]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"moxifloxacin\"]], \"start\": [[35]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"Torsade de pointes\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Severity\": {\"text\": [[\"fatal\"]], \"start\": [[72]], \"entity_id\": [\"T6\"], \"value\": \"High\"}}"
}
]
}
] |
25417855_3 | We report serious adverse effects due to interaction between orally administered voriconazole and everolimus in a renal transplant recipient. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"due to\"]], \"start\": [[34]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"serious adverse effects\"]], \"start\": [[10]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"interaction between orally administered voriconazole and everolimus\"]], \"start\": [[41]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"voriconazole\"], [\"everolimus\"]], \"start\": [[81], [98]], \"entity_id\": [\"T12\", \"T13\"]}, \"Route\": {\"text\": [[\"orally\"]], \"start\": [[61]], \"entity_id\": [\"T1\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"interaction\"]], \"start\": [[41]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"voriconazole\"], [\"everolimus\"]], \"start\": [[81], [98]], \"entity_id\": [\"T12\", \"T13\"]}}]}, \"Subject\": {\"text\": [[\"a renal transplant recipient\"]], \"start\": [[112]], \"entity_id\": [\"T9\"], \"Disorder\": {\"text\": [[\"renal transplant\"]], \"start\": [[114]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
2554727_1 | Horner's syndrome and demyelinating peripheral neuropathy caused by high-dose cytosine arabinoside. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"caused\"]], \"start\": [[58]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Horner's syndrome and demyelinating peripheral neuropathy\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"high-dose cytosine arabinoside\"]], \"start\": [[68]], \"entity_id\": [\"T7\"], \"Dosage\": {\"text\": [[\"high-dose\"]], \"start\": [[68]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"cytosine arabinoside\"]], \"start\": [[78]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
16097572_1 | Fatal radiation myelopathy after high-dose busulfan and melphalan chemotherapy and radiotherapy for Ewing's sarcoma: a review of the literature and implications for practice. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[27]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"radiation myelopathy\"]], \"start\": [[6]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"high-dose busulfan\", \"melphalan\"]], \"start\": [[33, 56]], \"entity_id\": [\"T5\"], \"Dosage\": {\"text\": [[\"high-dose\"]], \"start\": [[33]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"busulfan\"], [\"melphalan\"]], \"start\": [[43], [56]], \"entity_id\": [\"T9\", \"T10\"]}, \"Disorder\": {\"text\": [[\"Ewing's sarcoma:\"]], \"start\": [[100]], \"entity_id\": [\"T12\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[52]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"busulfan\"], [\"melphalan\"]], \"start\": [[43], [56]], \"entity_id\": [\"T9\", \"T10\"]}}]}, \"Severity\": {\"text\": [[\"Fatal\"]], \"start\": [[0]], \"entity_id\": [\"T13\"], \"value\": \"High\"}}"
}
]
}
] |
8053440_4 | This is the first description, to our knowledge, of ductopenia apparently caused by clindamycin. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"caused\"]], \"start\": [[74]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"ductopenia\"]], \"start\": [[52]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"clindamycin\"]], \"start\": [[84]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"clindamycin\"]], \"start\": [[84]], \"entity_id\": [\"T7\"]}}, \"Speculated\": {\"text\": [[\"to our knowledge\"]], \"start\": [[31]], \"entity_id\": [\"T6\"], \"value\": true}}"
}
]
}
] |
7781845_1 | Mefloquine-associated hypoglycaemia in a cachectic AIDS patient. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[11]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"Mefloquine\"]], \"start\": [[0]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"Mefloquine\"]], \"start\": [[0]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"hypoglycaemia\"]], \"start\": [[22]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"cachectic AIDS patient\"]], \"start\": [[41]], \"entity_id\": [\"T9\"], \"Disorder\": {\"text\": [[\"cachectic AIDS\"]], \"start\": [[41]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
19226083_17 | Patients who commonly require linezolid as an antimicrobial are those with complex infections where other antibiotic treatment has failed. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"require\"]], \"start\": [[22]], \"entity_id\": [\"T9\"]}, \"Subject\": {\"text\": [[\"Patients\", \"complex infections\"]], \"start\": [[0, 75]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"linezolid as an antimicrobial\"]], \"start\": [[30]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"linezolid\"]], \"start\": [[30]], \"entity_id\": [\"T10\"]}, \"Disorder\": {\"text\": [[\"complex infections\"]], \"start\": [[75]], \"entity_id\": [\"T11\"]}}}"
}
]
}
] |
6245286_2 | In three of these patients the infection was clinically unsuspected; in the fourth, cutaneous herpes zoster developed after administration of 300 mg of cytarabine daily for the preceding five days. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[108]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"three of these patients\"]], \"start\": [[3]], \"entity_id\": [\"T3\"], \"Population\": {\"text\": [[\"three\"]], \"start\": [[3]], \"entity_id\": [\"T7\"]}}, \"Treatment\": {\"text\": [[\"300 mg of cytarabine daily for the preceding five days\"]], \"start\": [[142]], \"entity_id\": [\"T4\"], \"Dosage\": {\"text\": [[\"300 mg\"]], \"start\": [[142]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"cytarabine\"]], \"start\": [[152]], \"entity_id\": [\"T9\"]}, \"Freq\": {\"text\": [[\"daily\"]], \"start\": [[163]], \"entity_id\": [\"T10\"]}, \"Duration\": {\"text\": [[\"preceding five days\"]], \"start\": [[177]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"cutaneous herpes zoster\"]], \"start\": [[84]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
17655517_9 | Patients receiving linezolid for more than 28 days should be monitored for signs of peripheral and optic neuropathy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"monitored\"]], \"start\": [[61]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"linezolid for more than 28 days\"]], \"start\": [[19]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"linezolid\"]], \"start\": [[19]], \"entity_id\": [\"T11\"]}, \"Duration\": {\"text\": [[\"28 days\"]], \"start\": [[43]], \"entity_id\": [\"T13\"]}}, \"Subject\": {\"text\": [[\"Patients\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"peripheral and optic neuropathy\"]], \"start\": [[84]], \"entity_id\": [\"T9\"]}, \"Speculated\": {\"text\": [[\"should\"]], \"start\": [[51]], \"entity_id\": [\"T12\"], \"value\": true}}"
}
]
}
] |
3941210_1 | Atrioventricular block complicating amiodarone-induced hypothyroidism in a patient with pre-excitation and rate-dependent bilateral bundle branch block. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[47]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"amiodarone\"]], \"start\": [[36]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"amiodarone\"]], \"start\": [[36]], \"entity_id\": [\"T10\"]}}, \"Subject\": {\"text\": [[\"a patient with pre-excitation and rate-dependent bilateral bundle branch block\"]], \"start\": [[73]], \"entity_id\": [\"T8\"], \"Disorder\": {\"text\": [[\"pre-excitation\"], [\"rate-dependent bilateral bundle branch block\"], [\"Atrioventricular block\"]], \"start\": [[88], [107], [0]], \"entity_id\": [\"T9\", \"T1\", \"T2\"]}}, \"Effect\": {\"text\": [[\"hypothyroidism\"]], \"start\": [[55]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
7249424_1 | Lithium is known to cause acute renal failure and tubulo-interstitial disease, but the recently described association with proteinuria or nephrotic syndrome is little recognized. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"association\"]], \"start\": [[106]], \"entity_id\": [\"T11\"]}, \"Treatment\": {\"text\": [[\"Lithium\"]], \"start\": [[0]], \"entity_id\": [\"T10\"], \"Drug\": {\"text\": [[\"Lithium\"]], \"start\": [[0]], \"entity_id\": [\"T13\"]}}, \"Effect\": {\"text\": [[\"acute renal failure and tubulo-interstitial disease\", \"proteinuria or nephrotic syndrome\"]], \"start\": [[26, 123]], \"entity_id\": [\"T12\"]}}"
}
]
}
] |
17509184_1 | A 40-year-old man with advanced HIV infection and Mycobacterium avium complex infection experienced rapid cognitive decline after commencement of ethambutol, and symptoms fully resolved with cessation. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[124]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"40-year-old man with advanced HIV infection and Mycobacterium avium complex infection\"]], \"start\": [[2]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"40-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T8\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[14]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"rapid cognitive decline\"]], \"start\": [[100]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"commencement of ethambutol\"]], \"start\": [[130]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"ethambutol\"]], \"start\": [[146]], \"entity_id\": [\"T11\"]}, \"Disorder\": {\"text\": [[\"ethambutol\"], [\"Mycobacterium avium complex infection\"], [\"HIV infection\"]], \"start\": [[146], [50], [32]], \"entity_id\": [\"T12\", \"T13\", \"T14\"]}}}"
}
]
}
] |
19892516_2 | Ciprofloxacin-induced hemorrhagic vasculitis is a rare side effect. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[14]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Ciprofloxacin\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Ciprofloxacin\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"hemorrhagic vasculitis\"]], \"start\": [[22]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
15028964_7 | Given that significant thyroid disorders may be only mildly symptomatic and thus may escape clinical detection, we suggest that thyroid function should be tested in any patient with otherwise unexplained changes in warfarin dose requirements, particularly if concomitantly treated with amiodarone. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"changes\"]], \"start\": [[204]], \"entity_id\": [\"T9\"]}, \"Effect\": {\"text\": [[\"significant thyroid disorders\"]], \"start\": [[11]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"warfarin\", \"with amiodarone\"]], \"start\": [[215, 281]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"warfarin\"], [\"amiodarone\"]], \"start\": [[215], [286]], \"entity_id\": [\"T10\", \"T11\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"concomitantly\"]], \"start\": [[259]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"amiodarone\"], [\"warfarin\"]], \"start\": [[286], [215]], \"entity_id\": [\"T11\", \"T10\"]}}]}}"
}
]
}
] |
10367184_1 | Myotonia associated with sarcoidosis: marked exacerbation with pravastatin. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[9]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"pravastatin\"]], \"start\": [[63]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"pravastatin\"]], \"start\": [[63]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"exacerbation\", \"Myotonia\"]], \"start\": [[45, 0]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"sarcoidosis\"]], \"start\": [[25]], \"entity_id\": [\"T8\"], \"Disorder\": {\"text\": [[\"sarcoidosis\"]], \"start\": [[25]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
7668127_5 | This observation questions the suitability of aspirin as prophylaxis for vascular disease in patients with meningiomas. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"prophylaxis\"]], \"start\": [[57]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"aspirin\"]], \"start\": [[46]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"aspirin\"]], \"start\": [[46]], \"entity_id\": [\"T12\"]}, \"Disorder\": {\"text\": [[\"vascular disease\"]], \"start\": [[73]], \"entity_id\": [\"T13\"]}}, \"Subject\": {\"text\": [[\"patients with meningiomas\"]], \"start\": [[93]], \"entity_id\": [\"T10\"], \"Disorder\": {\"text\": [[\"meningiomas\"]], \"start\": [[107]], \"entity_id\": [\"T11\"]}}, \"Speculated\": {\"text\": [[\"questions\"]], \"start\": [[17]], \"entity_id\": [\"T14\"], \"value\": true}}"
}
]
}
] |
8360712_2 | Delayed neurotoxicity of intraventricular interleukin-2: a case report. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"of\"]], \"start\": [[22]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Delayed neurotoxicity\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"intraventricular interleukin-2\"]], \"start\": [[25]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"interleukin-2\"]], \"start\": [[42]], \"entity_id\": [\"T7\"]}, \"Route\": {\"text\": [[\"intraventricular\"]], \"start\": [[25]], \"entity_id\": [\"T8\"]}}, \"Subject\": {\"text\": [[\"a case report\"]], \"start\": [[57]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
7776854_4 | We stress the potential of benzarone to cause hepatotoxicity, which usually resembles severe chronic active hepatitis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"cause\"]], \"start\": [[40]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"hepatotoxicity\", \"severe chronic active hepatitis\"]], \"start\": [[46, 86]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"benzarone\"]], \"start\": [[27]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"benzarone\"]], \"start\": [[27]], \"entity_id\": [\"T11\"]}}, \"Speculated\": {\"text\": [[\"potential\"]], \"start\": [[14]], \"entity_id\": [\"T9\"], \"value\": true}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[86]], \"entity_id\": [\"T10\"], \"value\": \"Medium\"}}"
}
]
}
] |
3579660_3 | We describe a patient with Wilson's disease who presented with neurologic disease, was treated with D-penicillamine, and suffered sudden neurologic deterioration coincident with therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"suffered\"]], \"start\": [[121]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"a patient with Wilson's disease who presented with neurologic disease\"]], \"start\": [[12]], \"entity_id\": [\"T3\"], \"Disorder\": {\"text\": [[\"neurologic disease\"]], \"start\": [[63]], \"entity_id\": [\"T1\"]}}, \"Effect\": {\"text\": [[\"sudden neurologic deterioration\"]], \"start\": [[130]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"D-penicillamine\"]], \"start\": [[100]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"Wilson's disease\"]], \"start\": [[27]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"D-penicillamine\"]], \"start\": [[100]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
16889287_3 | We report the case of a 21-year-old female patient with dapsone hypersensitivity syndrome. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"with\"]], \"start\": [[51]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"a 21-year-old female patient\"]], \"start\": [[22]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"21-year-old\"]], \"start\": [[24]], \"entity_id\": [\"T7\"]}, \"Gender\": {\"text\": [[\"female\"]], \"start\": [[36]], \"entity_id\": [\"T8\"]}}, \"Treatment\": {\"text\": [[\"dapsone\"]], \"start\": [[56]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"dapsone\"]], \"start\": [[56]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"hypersensitivity syndrome\"]], \"start\": [[64]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
22233409_5 | The adverse events related to ribavirin and drug-drug interactions during therapy for hepatitis C are discussed. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"related\"]], \"start\": [[19]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"ribavirin\"]], \"start\": [[30]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"ribavirin\"]], \"start\": [[30]], \"entity_id\": [\"T9\"]}, \"Disorder\": {\"text\": [[\"hepatitis C\"]], \"start\": [[86]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"adverse events\"]], \"start\": [[4]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
2309833_3 | Insulin-dependent diabetes mellitus developed in a young woman 8 weeks after the initiation of danazol for treatment of pelvic endometriosis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[71]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"8 weeks after the initiation of danazol\"]], \"start\": [[63]], \"entity_id\": [\"T4\"], \"Disorder\": {\"text\": [[\"pelvic endometriosis\"]], \"start\": [[120]], \"entity_id\": [\"T5\"]}, \"Time_elapsed\": {\"text\": [[\"8 weeks\"]], \"start\": [[63]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"danazol\"]], \"start\": [[95]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"Insulin-dependent diabetes mellitus\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"a young woman\"]], \"start\": [[49]], \"entity_id\": [\"T7\"], \"Age\": {\"text\": [[\"young\"]], \"start\": [[51]], \"entity_id\": [\"T8\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[57]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
417679_1 | Four cases of fat embolism are described in infants receiving prolonged intravenous infusion of fat (Intralipid 20%). | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"receiving\"]], \"start\": [[52]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"fat embolism\"]], \"start\": [[14]], \"entity_id\": [\"T3\"]}, \"Subject\": {\"text\": [[\"Four cases\", \"infants\"]], \"start\": [[0, 44]], \"entity_id\": [\"T4\"], \"Age\": {\"text\": [[\"infants\"], [\"Four\"]], \"start\": [[44], [0]], \"entity_id\": [\"T7\", \"T8\"]}}, \"Treatment\": {\"text\": [[\"prolonged intravenous infusion of fat (Intralipid 20%)\"]], \"start\": [[62]], \"entity_id\": [\"T5\"], \"Route\": {\"text\": [[\"intravenous infusion\"]], \"start\": [[72]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"Intralipid\"]], \"start\": [[101]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
18176653_1 | Oral adverse effects due to the use of Nevirapine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"due\"]], \"start\": [[21]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Nevirapine\"]], \"start\": [[39]], \"entity_id\": [\"T5\"], \"Route\": {\"text\": [[\"Oral\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}, \"Drug\": {\"text\": [[\"Nevirapine\"]], \"start\": [[39]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"adverse effects\"]], \"start\": [[5]], \"entity_id\": [\"T3\"]}}"
}
]
}
] |
19299370_4 | PURPOSE: A case of probable enoxaparin-induced hepatotoxicity is described. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[39]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"enoxaparin\"]], \"start\": [[28]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"enoxaparin\"]], \"start\": [[28]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"hepatotoxicity\"]], \"start\": [[47]], \"entity_id\": [\"T6\"]}, \"Speculated\": {\"text\": [[\"probable\"]], \"start\": [[19]], \"entity_id\": [\"T3\"], \"value\": true}}"
}
]
}
] |
15383642_9 | Tizanidine was used again after her BP had stabilized, but did not produce similar problems. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"produce\"]], \"start\": [[67]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"Tizanidine\"]], \"start\": [[0]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"Tizanidine\"]], \"start\": [[0]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"problems\"]], \"start\": [[83]], \"entity_id\": [\"T8\"]}, \"Negated\": {\"text\": [[\"not\"]], \"start\": [[63]], \"entity_id\": [\"T5\"], \"value\": true}}"
}
]
}
] |
424824_3 | It is suggested therefore that methotrexate be added to the list of agents capable of inducing diffuse interstitial pulmonary fibrosis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"inducing\"]], \"start\": [[86]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"methotrexate\"]], \"start\": [[31]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"methotrexate\"]], \"start\": [[31]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"diffuse interstitial pulmonary fibrosis\"]], \"start\": [[95]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
8816294_1 | The delayed encephalopathy developed 9 and 22 months respectively after the first dose of intrathecal methotrexate. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[27]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"delayed encephalopathy\"]], \"start\": [[4]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"intrathecal methotrexate\"]], \"start\": [[90]], \"entity_id\": [\"T5\"], \"Time_elapsed\": {\"text\": [[\"9 and 22 months\"]], \"start\": [[37]], \"entity_id\": [\"T6\"]}, \"Dosage\": {\"text\": [[\"methotrexate\"]], \"start\": [[102]], \"entity_id\": [\"T7\"]}, \"Route\": {\"text\": [[\"intrathecal\"]], \"start\": [[90]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
3565435_2 | Severe systemic hypersensitivity reaction to ibuprofen occurring after prolonged therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[65]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"ibuprofen\", \"prolonged therapy\"]], \"start\": [[45, 71]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"ibuprofen\"]], \"start\": [[45]], \"entity_id\": [\"T7\"]}, \"Time_elapsed\": {\"text\": [[\"prolonged therapy\"]], \"start\": [[71]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"Severe systemic hypersensitivity reaction\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Severity\": {\"text\": [[\"Severe\"]], \"start\": [[0]], \"entity_id\": [\"T6\"], \"value\": \"High\"}}"
}
]
}
] |
11250985_2 | In patients with chronic heart failure, spironolactone added to conventional treatment may lead to serious and, occasionally, fatal hyperkalaemia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"lead\"]], \"start\": [[91]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"spironolactone\"]], \"start\": [[40]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"spironolactone\"]], \"start\": [[40]], \"entity_id\": [\"T9\"]}}, \"Subject\": {\"text\": [[\"patients with chronic heart failure\"]], \"start\": [[3]], \"entity_id\": [\"T4\"], \"Disorder\": {\"text\": [[\"chronic heart failure\"]], \"start\": [[17]], \"entity_id\": [\"T5\"]}}, \"Effect\": {\"text\": [[\"serious and, occasionally, fatal hyperkalaemia\"]], \"start\": [[99]], \"entity_id\": [\"T6\"]}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[87]], \"entity_id\": [\"T7\"], \"value\": true}}"
}
]
}
] |
10516999_2 | We report a case of acute hyperphosphatemia secondary to rectal administration of sodium phosphate and sodium biphosphate (Fleet enema). | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"secondary\"]], \"start\": [[44]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"acute hyperphosphatemia\"]], \"start\": [[20]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"rectal administration of sodium phosphate and sodium biphosphate (Fleet enema)\"]], \"start\": [[57]], \"entity_id\": [\"T6\"], \"Route\": {\"text\": [[\"rectal\"]], \"start\": [[57]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"sodium phosphate\"], [\"sodium biphosphate\"]], \"start\": [[82], [103]], \"entity_id\": [\"T8\", \"T9\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[99]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"sodium phosphate\"], [\"sodium biphosphate\"]], \"start\": [[82], [103]], \"entity_id\": [\"T8\", \"T9\"]}}]}}"
}
]
}
] |
12365708_4 | Visual changes secondary to initiation of amiodarone: a case report and review involving ocular management in cardiac polypharmacy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"secondary\"]], \"start\": [[15]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"Visual changes\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"amiodarone\"]], \"start\": [[42]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"amiodarone\"]], \"start\": [[42]], \"entity_id\": [\"T7\"]}}, \"Subject\": {\"text\": [[\"a case\"]], \"start\": [[54]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
14674674_3 | This is the first case, to our knowledge, of onset of prolonged infliximab-induced lupus. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[75]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"lupus\"]], \"start\": [[83]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"infliximab\"]], \"start\": [[64]], \"entity_id\": [\"T4\"], \"Duration\": {\"text\": [[\"prolonged\"]], \"start\": [[54]], \"entity_id\": [\"T6\"]}, \"Drug\": {\"text\": [[\"infliximab\"]], \"start\": [[64]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
17420198_19 | A patient with developmental disabilities who had no history of movement disorders developed EPS following initiation of aripiprazole. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[97]], \"entity_id\": [\"T10\"]}, \"Effect\": {\"text\": [[\"EPS\"]], \"start\": [[93]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"initiation of aripiprazole\"]], \"start\": [[107]], \"entity_id\": [\"T11\"], \"Drug\": {\"text\": [[\"aripiprazole\"]], \"start\": [[121]], \"entity_id\": [\"T13\"]}}, \"Subject\": {\"text\": [[\"A patient with developmental disabilities who had no history of movement disorders\"]], \"start\": [[0]], \"entity_id\": [\"T8\"], \"Disorder\": {\"text\": [[\"developmental disabilities\"]], \"start\": [[15]], \"entity_id\": [\"T1\"]}}}"
}
]
}
] |
15307435_1 | Case report: life-threatening hypoglycaemia associated with sulfadoxine-pyrimethamine, a commonly used antimalarial drug. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[44]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"life-threatening hypoglycaemia\"]], \"start\": [[13]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"sulfadoxine-pyrimethamine\"]], \"start\": [[60]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"sulfadoxine-pyrimethamine\"]], \"start\": [[60]], \"entity_id\": [\"T7\"]}}, \"Subject\": {\"text\": [[\"Case\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
12811715_2 | Diphenhydramine-induced wide complex dysrhythmia responds to treatment with sodium bicarbonate. | false | [
{
"events": [
{
"event_id": "E2",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"to\"]], \"start\": [[58]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"treatment with sodium bicarbonate\"]], \"start\": [[61]], \"entity_id\": [\"T4\"], \"Disorder\": {\"text\": [[\"Diphenhydramine-induced wide complex dysrhythmia\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Drug\": {\"text\": [[\"Diphenhydramine\"], [\"sodium bicarbonate\"]], \"start\": [[0], [76]], \"entity_id\": [\"T7\", \"T8\"]}}}"
}
]
}
] |
228648_1 | Prenatal cytomegalovirus (CMV) infection associated with severe brain damage was detected in an infant whose mother had been treated with prednisolone and azathioprine for systemic lupus erythematosus (SLE). | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"treated\"]], \"start\": [[125]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"Prenatal cytomegalovirus (CMV) infection associated with severe brain damage\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"prednisolone and azathioprine\"]], \"start\": [[138]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"prednisolone\"], [\"azathioprine\"]], \"start\": [[138], [155]], \"entity_id\": [\"T12\", \"T13\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[151]], \"entity_id\": [\"T14\"]}, \"Drug\": {\"text\": [[\"prednisolone\"], [\"azathioprine\"]], \"start\": [[138], [155]], \"entity_id\": [\"T12\", \"T13\"]}}]}, \"Subject\": {\"text\": [[\"an infant whose mother had been treated with prednisolone and azathioprine for systemic lupus erythematosus (SLE)\"]], \"start\": [[93]], \"entity_id\": [\"T10\"], \"Age\": {\"text\": [[\"infant\"]], \"start\": [[96]], \"entity_id\": [\"T11\"]}}}"
}
]
}
] |
20178709_2 | Methotrexate may rarely provoke serositis, even with low doses and after just a few weeks of therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"provoke\"]], \"start\": [[24]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"Methotrexate\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Methotrexate\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"serositis\"]], \"start\": [[32]], \"entity_id\": [\"T4\"]}}"
}
]
}
] |
21597286_6 | Prescription analyses by pharmacists and literature research have permitted us to suggest that a drug-drug interaction between methotrexate and proton pump inhibitors (PPI) was responsible for this renal failure. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"responsible\"]], \"start\": [[177]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"methotrexate and proton pump inhibitors (PPI)\"]], \"start\": [[127]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"methotrexate\"], [\"proton pump inhibitors (PPI)\"]], \"start\": [[127], [144]], \"entity_id\": [\"T10\", \"T11\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"interaction\"]], \"start\": [[107]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"methotrexate\"], [\"proton pump inhibitors (PPI)\"]], \"start\": [[127], [144]], \"entity_id\": [\"T10\", \"T11\"]}}]}, \"Effect\": {\"text\": [[\"renal failure\"]], \"start\": [[198]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
18795_2 | Asthma and urticaria during disodium cromoglycate treatment. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"during\"]], \"start\": [[21]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Asthma and urticaria\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"disodium cromoglycate treatment\"]], \"start\": [[28]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"disodium cromoglycate\"]], \"start\": [[28]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
10679548_7 | We suggest that the previous classification of nitrofurantoin induced lung injury into "acute" and "chronic" injury is an oversimplification in view of the wide variety of pathological entities that have subsequently emerged. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[62]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"nitrofurantoin\"]], \"start\": [[47]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"nitrofurantoin\"]], \"start\": [[47]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"lung injury\"]], \"start\": [[70]], \"entity_id\": [\"T4\"]}}"
}
]
}
] |
2369419_2 | Hepatitis with bridging fibrosis and reversible hepatic insufficiency in a woman with rheumatoid arthritis taking methotrexate. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"taking\"]], \"start\": [[107]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"methotrexate\"]], \"start\": [[114]], \"entity_id\": [\"T8\"], \"Disorder\": {\"text\": [[\"rheumatoid arthritis\"]], \"start\": [[86]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"methotrexate\"]], \"start\": [[114]], \"entity_id\": [\"T13\"]}}, \"Subject\": {\"text\": [[\"a woman with rheumatoid arthritis\"]], \"start\": [[73]], \"entity_id\": [\"T9\"], \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[75]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"Hepatitis with bridging fibrosis and reversible hepatic insufficiency\"]], \"start\": [[0]], \"entity_id\": [\"T10\"]}}"
}
]
}
] |
16116136_4 | Primary CNS lymphoma regressed on withdrawal of MM. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"regressed\"]], \"start\": [[21]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"withdrawal of MM\"]], \"start\": [[34]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"MM\"]], \"start\": [[48]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"Primary CNS lymphoma\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}}"
}
]
}
] |
6498095_2 | Pemphigus foliaceus induced by rifampicin. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[20]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Pemphigus foliaceus\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"rifampicin\"]], \"start\": [[31]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"rifampicin\"]], \"start\": [[31]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
2931445_3 | L-T4 stimulated lymphocyte transformation in this patient. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"stimulated\"]], \"start\": [[5]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"L-T4\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"L-T4\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"lymphocyte transformation\"]], \"start\": [[16]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"this patient\"]], \"start\": [[45]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
12126225_1 | A 53-year-old man developed lower leg edema 4 weeks after rosiglitazone was increased from 4 mg once/day to 4 mg twice/day. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[52]], \"entity_id\": [\"T3\"]}, \"Subject\": {\"text\": [[\"A 53-year-old man\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Age\": {\"text\": [[\"53-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T7\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[14]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"lower leg edema\"]], \"start\": [[28]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"4 weeks after rosiglitazone was increased from 4 mg once/day to 4 mg twice/day\"]], \"start\": [[44]], \"entity_id\": [\"T6\"], \"Time_elapsed\": {\"text\": [[\"4 weeks\"]], \"start\": [[44]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"rosiglitazone\"]], \"start\": [[58]], \"entity_id\": [\"T10\"]}, \"Dosage\": {\"text\": [[\"4 mg\"]], \"start\": [[108]], \"entity_id\": [\"T11\"]}, \"Freq\": {\"text\": [[\"twice/day\"]], \"start\": [[113]], \"entity_id\": [\"T12\"]}}}"
}
]
}
] |
3143551_2 | A mentally retarded 23-year-old woman with myoclonic astatic epilepsy developed an abnormal posture of extreme forward flexion, called camptocormia, during valproate monotherapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"during\"]], \"start\": [[149]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"valproate\"]], \"start\": [[156]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"valproate\"]], \"start\": [[156]], \"entity_id\": [\"T12\"]}, \"Disorder\": {\"text\": [[\"myoclonic astatic epilepsy\"]], \"start\": [[43]], \"entity_id\": [\"T13\"]}}, \"Subject\": {\"text\": [[\"A mentally retarded 23-year-old woman with myoclonic astatic epilepsy\"]], \"start\": [[0]], \"entity_id\": [\"T7\"], \"Disorder\": {\"text\": [[\"mentally retarded\"]], \"start\": [[2]], \"entity_id\": [\"T9\"]}, \"Age\": {\"text\": [[\"23-year-old\"]], \"start\": [[20]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"abnormal posture of extreme forward flexion, called camptocormia,\"]], \"start\": [[83]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
12086549_1 | After 5 days of treatment with IL-2, the patient developed a hemorrhagic lesion that progressed to toxic epidermal necrolysis, as well as grade 4 pancytopenia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[49]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"5 days of treatment with IL-2\"]], \"start\": [[6]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"IL-2\"]], \"start\": [[31]], \"entity_id\": [\"T11\"]}, \"Time_elapsed\": {\"text\": [[\"After 5 days\"]], \"start\": [[0]], \"entity_id\": [\"T12\"]}}, \"Subject\": {\"text\": [[\"patient\"]], \"start\": [[41]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"a hemorrhagic lesion that progressed to toxic epidermal necrolysis, as well as grade 4 pancytopenia\"]], \"start\": [[59]], \"entity_id\": [\"T9\"]}}"
}
]
}
] |
9399776_1 | Acute pancreatitis after long-term 5-aminosalicylic acid therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[19]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"Acute pancreatitis\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"long-term 5-aminosalicylic acid therapy\"]], \"start\": [[25]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"5-aminosalicylic acid\"]], \"start\": [[35]], \"entity_id\": [\"T6\"]}, \"Time_elapsed\": {\"text\": [[\"long-term\"]], \"start\": [[25]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |